Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era-Reference-Cited by-同舟云学术

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era

Published:2013-08-01 Issue:10 Volume:88 Page:890-894
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Nagle Sarah J.¹,Woo Kaitlin²,Schuster Stephen J.¹,Nasta Sunita D.¹,Stadtmauer Edward¹,Mick Rosemarie²,Svoboda Jakub¹

Affiliation:

1. Lymphoma Program, Abramson Cancer Center; University of Pennsylvania; Philadelphia Pennsylvania

2. Department of Biostatistics & Epidemiology; University of Pennsylvania; Philadelphia Pennsylvania

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23524/fullpdf

Reference12 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte;Feugier;J Clin Oncol,2005

4. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005

5. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group;Pfreundschuh;Lancet Oncol,2006

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey;Frontiers in Oncology;2024-06-24

3. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings;Advanced Drug Delivery Reviews;2024-04

4. Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation;Cells;2024-03-21

5. A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma;PharmacoEconomics - Open;2024-01-10